SEHK:2595Biotechs
GenFleet Therapeutics SEHK 2595 Deepens Losses As Revenue Growth Tests Bullish Narratives
GenFleet Therapeutics (Shanghai) (SEHK:2595) has just released its FY 2025 figures, with first half revenue at C¥88.7 million and basic EPS at a loss of C¥27.02 per share, setting the tone for a period where margins remain firmly in loss-making territory. The company has seen first half revenue move from C¥0 in 2024 to C¥88.7 million in 2025, while basic EPS shifted from a loss of C¥18.02 to a deeper loss of C¥27.02. This puts the spotlight on how quickly revenue can scale against persistent...